Analyst Corner: Glenmark Pharma Rating ‘hold’ – A healthy performance in the quarter

By: |
Published: July 6, 2020 1:01 AM

Covid-19 poses near-term challenges; downgraded to Hold with revised TP of Rs 475

GNP’s stock price has risen 35.3% in 2020 YTD (including a single day gain of 26.97% on 22 June on FabiFlu approval by the Indian regulator.

Despite COVID-19 disruptions, GNP reported revenues of Rs 27.7 bn in Q4, which grew 8% y-o-y as it benefitted from customers stocking up in India to avoid supply uncertainties. India sales at Rs 7.6 bn grew 14.5% y-o-y. It also benefitted from additional supplies in Italy. Gross margins (GM) at 64.7% fell 170bps y-o-y as it continues to face price erosion in its US derma portfolio. Despite lower GM, its Ebitda margin at 16.8% improved 262bps y-o-y on tight control of other operating costs (incl. R&D). Reported PAT at Rs 2.2 bn (+36.3% y-o-y) included a one-off benefit of Rs 329 m.

Near term will be challenging: Q1FY21 will be challenging for most of its segments due to COVID-19, according to GNP. It expects a gradual recovery in growth for key markets like India and the US. Ichnos Sciences (its innovation business) has initiated a process to raise capital in the US. A successful capital raise will significantly ease R&D burden for GNP.

Downgrade to Hold: GNP’s stock price has risen 35.3% in 2020 YTD (including a single day gain of 26.97% on 22 June on FabiFlu approval by the Indian regulator as an emergency treatment for COVID-19) vs a decline of 15.4% for Sensex. We believe this largely factors in upside from an expected operational turnaround and debt reduction, where GNP is yet to show results. We believe further re-rating would need to be backed by notable improvement in execution.

We downgrade GNP to Hold from Buy as we look for improved execution. We make minor changes (2-3%) to our FY21-22 estimates after Q4 results. We value GNP’s base business by discounting our one-year forward fair value estimate. To the base business value, we add our NPV forecast for the R&D pipeline to arrive at our TP of Rs 475 (from Rs 360).

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Companies post worst profit decline in a decade, but market analysts are happy about it
2ICICI Bank closes QIP after raising Rs 15,000 crore; sells shares at 1.9% premium to floor price
3How new-age banking solution geared with AI can help make wise investment decisions